HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Neutral 52.5%

Neg 0% Neu 52.5% Pos 0%

HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.